Adicet Bio is a clinical-stage biotechnology company focused on discovering and developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Their proprietary platform engineers these cells with chimeric antigen receptors (CARs) to provide durable activity in patients. The company's lead product candidate, prulacabtagene leucel (prula-cel), is being developed for autoimmune indications and has received Fast Track Designation from the FDA for certain conditions.